Vertically integrated fertility clinic network and family-building benefits provider
Kindbody operates a vertically integrated network of fertility clinics combined with an employer-benefits business that contracts with Fortune 500 customers for IVF and family-building coverage. The company reached a $1.8 billion valuation in its 2023 Series D, but spent 2024 restructuring — shuttering underperforming clinics and shuffling its C-suite before founder Gina Bartasi returned as CEO. Management has since guided to $225-$250M in 2024 revenue with the business now profitable after years of losses.
Healthcare📍 New York, NYFounded 2018
Current Valuation
$1.8B
as of 2023-Q1
UNICORN
QL Price
$1.8B
0% vs last round
QuantLogix's current estimate for Kindbody, published 2026-09-12 — in line with the last disclosed round of $1.8B (2023-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.8B
2023-Q1
weight 0.09
Secondary market print
$1.8B
2026-06-27
weight 0.63
How this price has held up
No round has priced for Kindbody since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-12 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Kindbody, 2026-09-12 (b7c8a51d957ec1ea).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Kindbody going public?
No. Kindbody is private and has not filed to go public. There is no S-1 on file.
What is Kindbody's valuation in 2026?
Kindbody is valued at $1.8B as of 2023-Q1, set by its Series D ($66.21M, May 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Gina Bartasi
Founded
2018
HQ
New York, NY
Employees
~1100
Total Raised
$315M
Est. Revenue
$237.5M (2024)
Growth
Path to profitability after restructuring
Last Round
Series D — $66.21M (May 2023) · Lead: Perceptive Advisors
IPO Status
private
Fundraising Status
Series D · $66.21M · 3y 4mo ago
privateTotal raised $315M
Secondary Market
Implied price / share
$23.85
Open interest
3
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$66.21M
May 2023
Perceptive Advisors
—
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
5
via careers page
Product-build share
100%
engineering, research, product, design
Trajectory
steady
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 5 of 5 open roles are medical.
Counted from Kindbody's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Gina Bartasi
Investors
Perceptive Advisors · Claritas Capital · GV · RRE Ventures · Tribe Capital
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.